Stem Cell Therapy to Treat Heart Ischaemia: Implications for Diabetes Cardiovascular Complications

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2014 Oct 27

PMID 25344789

Citations 5

Authors

Abbas Ali Qayyum

Anders Bruun Mathiasen

Jens Kastrup

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus is a well-known risk factor for coronary artery disease (CAD), which can lead to acute myocardial infarction, chronic myocardial ischaemia and heart failure. Despite the advantages in medical treatment, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), morbidity and mortality is still high in patients with CAD. Along with PCI and CABG or in patients without options for revascularization, stem cell regenerative therapy in controlled trials is a possibility. Stem cells are believed to exert their actions by angiogenesis and regeneration of cardiomyocytes. Recently published clinical trials and meta-analysis of stem cell studies have shown encouraging results with increased left ventricle ejection fraction and reduced symptoms in patients with CAD and heart failure. There is some evidence of mesenchymal stem cell being more effective compared to other cell types and cell therapy may be more effective in patients with known diabetes mellitus. However, further investigations are warranted.

Citing Articles

Adipose-derived mesenchymal stem cells-derived exosome-mediated microRNA-342-5p protects endothelial cells against atherosclerosis.

Xing X, Li Z, Yang X, Li M, Liu C, Pang Y Aging (Albany NY). 2020; 12(4):3880-3898.

PMID: 32096479 PMC: 7066923. DOI: 10.18632/aging.102857.

GATA-4-expressing mouse bone marrow mesenchymal stem cells improve cardiac function after myocardial infarction via secreted exosomes.

He J, Li H, Han J, Li B, Yan D, Li H Sci Rep. 2018; 8(1):9047.

PMID: 29899566 PMC: 5998064. DOI: 10.1038/s41598-018-27435-9.

Adult Versus Pluripotent Stem Cell-Derived Mesenchymal Stem Cells: The Need for More Precise Nomenclature.

West M, Nasonkin I, LaRocca D, Chapman K, Binette F, Sternberg H Curr Stem Cell Rep. 2016; 2:299-303.

PMID: 27547711 PMC: 4972883. DOI: 10.1007/s40778-016-0060-6.

Fibroblast Growth Factor-9 Activates c-Kit Progenitor Cells and Enhances Angiogenesis in the Infarcted Diabetic Heart.

Singla D, Wang J Oxid Med Cell Longev. 2015; 2016:5810908.

PMID: 26682010 PMC: 4670684. DOI: 10.1155/2016/5810908.

Co-administration of aspirin and allogeneic adipose-derived stromal cells attenuates bone loss in ovariectomized rats through the anti-inflammatory and chemotactic abilities of aspirin.

Liu H, Li W, Liu Y, Zhang X, Zhou Y Stem Cell Res Ther. 2015; 6:200.

PMID: 26474767 PMC: 4609080. DOI: 10.1186/s13287-015-0195-x.

References

Helder M, Knippenberg M, Klein-Nulend J, Wuisman P . Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. Tissue Eng. 2007; 13(8):1799-808. DOI: 10.1089/ten.2006.0165. View

Dimitropoulos G, Tahrani A, Stevens M . Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014; 5(1):17-39. PMC: 3932425. DOI: 10.4239/wjd.v5.i1.17. View

Goumans M, de Boer T, Smits A, van Laake L, van Vliet P, Metz C . TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res. 2009; 1(2):138-49. DOI: 10.1016/j.scr.2008.02.003. View

Heldman A, DiFede D, Fishman J, Zambrano J, Trachtenberg B, Karantalis V . Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2013; 311(1):62-73. PMC: 4111133. DOI: 10.1001/jama.2013.282909. View

Qayyum A, Vejlstrup N, Ahtarovski K, Kofoed K, Kastrup J . Coronary artery stent mimicking intracardiac thrombus on cardiac magnetic resonance imaging due to signal loss: case report. Magn Reson Imaging. 2012; 30(6):889-92. DOI: 10.1016/j.mri.2012.02.023. View

Hare J, Traverse J, Henry T, Dib N, Strumpf R, Schulman S . A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24):2277-86. PMC: 3580848. DOI: 10.1016/j.jacc.2009.06.055. View

Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L . Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013; 15(9):1054-61. DOI: 10.1016/j.jcyt.2013.02.010. View

Williams A, Hare J . Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109(8):923-40. PMC: 3604746. DOI: 10.1161/CIRCRESAHA.111.243147. View

Bergmann O, Bhardwaj R, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S . Evidence for cardiomyocyte renewal in humans. Science. 2009; 324(5923):98-102. PMC: 2991140. DOI: 10.1126/science.1164680. View

10.

Takashima S, Tempel D, Duckers H . Current outlook of cardiac stem cell therapy towards a clinical application. Heart. 2013; 99(23):1772-84. DOI: 10.1136/heartjnl-2012-303308. View

11.

Fisher S, Brunskill S, Doree C, Mathur A, Taggart D, Martin-Rendon E . Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2014; (4):CD007888. DOI: 10.1002/14651858.CD007888.pub2. View

12.

Neef K, Choi Y, Weichel A, Rahmanian P, Liakopoulos O, Stamm C . The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy. 2012; 14(6):670-8. DOI: 10.3109/14653249.2012.663483. View

13.

Qayyum A, Hasbak P, Larsson H, Christensen T, Ghotbi A, Mathiasen A . Quantification of myocardial perfusion using cardiac magnetic resonance imaging correlates significantly to rubidium-82 positron emission tomography in patients with severe coronary artery disease: a preliminary study. Eur J Radiol. 2014; 83(7):1120-1128. DOI: 10.1016/j.ejrad.2014.04.004. View

14.

Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C . Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005; 45(9):1441-8. DOI: 10.1016/j.jacc.2004.12.074. View

15.

Nowbar A, Mielewczik M, Karavassilis M, Dehbi H, Shun-Shin M, Jones S . Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 2014; 348:g2688. PMC: 4002982. DOI: 10.1136/bmj.g2688. View

16.

Eurich D, Weir D, Majumdar S, Tsuyuki R, Johnson J, Tjosvold L . Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013; 6(3):395-402. DOI: 10.1161/CIRCHEARTFAILURE.112.000162. View

17.

Zimmet H, Porapakkham P, Porapakkham P, Sata Y, Haas S, Itescu S . Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail. 2011; 14(1):91-105. DOI: 10.1093/eurjhf/hfr148. View

18.

Friis T, Haack-Sorensen M, Mathiasen A, Ripa R, Kristoffersen U, Jorgensen E . Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand Cardiovasc J. 2011; 45(3):161-8. DOI: 10.3109/14017431.2011.569571. View

19.

Chan K, Raikwar S, Zavazava N . Strategies for differentiating embryonic stem cells (ESC) into insulin-producing cells and development of non-invasive imaging techniques using bioluminescence. Immunol Res. 2007; 39(1-3):261-70. DOI: 10.1007/s12026-007-0070-7. View

20.

Mathiasen A, Jorgensen E, Qayyum A, Haack-Sorensen M, Ekblond A, Kastrup J . Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). Am Heart J. 2012; 164(3):285-91. DOI: 10.1016/j.ahj.2012.05.026. View